Boltz PBC develops frontier AI models and computing infrastructure for scientific discovery, with a focus on biomolecular modeling and design in biology and chemistry. Its tools help scientists work with molecules across drug discovery and related research, and are designed to fit into existing scientific workflows and software.

The company offers Boltz API and Boltz Lab, providing access to models and capabilities for designing small molecules, designing proteins, and predicting structures. Its model portfolio includes BoltzMol-1, BoltzProt-1, Boltz-2, and BoltzGen; the site identifies some models as open-source. Boltz highlights small-molecule screening and hit discovery, including experimental validation at scale, and provides fast inference intended to support large design runs. Customers can choose multi-tenant, single-tenant, or on-premise deployment, and can fine-tune frontier models using proprietary data, targets, and assays. Boltz also offers developer access through Python and TypeScript tools. The company collaborates with scientific and industry partners, including teams tackling challenging drug-discovery problems, and invites organizations to explore partnerships.